Repros Therapeutics Inc. (NASDAQ:RPRX) saw an uptick in trading volume on Monday . 750,353 shares were traded during trading, an increase of 56% from the previous session’s volume of 479,489 shares.The stock last traded at $2.40 and had previously closed at $2.21.

Separately, Zacks Investment Research cut Repros Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. Repros Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $2.25.

The company has a 50 day moving average price of $1.87 and a 200 day moving average price of $1.61. The firm’s market cap is $50.24 million.

Repros Therapeutics (NASDAQ:RPRX) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.02. Equities research analysts anticipate that Repros Therapeutics Inc. will post ($0.70) EPS for the current fiscal year.

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include Androxal and Proellex. The Company’s primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.